28 completed, 3 withdrawn, 2 recruiting, 2 terminated. 19 Phase 2, 10 Phase 3, 7 Phase 1, 4 Phase 4, 1 Not applicable.
Follow Papulopustular Rosacea: new trials by email Literature Review of Papulopustular Rosacea trials Research Report on Papulopustular Rosacea
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR) LOU064, Placebo - Papulopustular Rosacea | Phase 2 | Recruiting | Novartis Pharmaceuticals | 100 | 2026-07-30 | 2026-10-15 |
| Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea Clascoterone Cream 1% - Papular-pustular Rosacea, Papulopustular Rosacea (PPR) | Phase 2 | Recruiting | Narrows Institute for Biomedical Research | 20 | 2025-03-14 | 2025-05-06 |
| Deucravacitinib Rosacea Deucravacitinib, Placebo - Papulopustular Rosacea | Phase 2 | Withdrawn | Icahn School of Medicine at Mount Sinai | 2024-11-01 | 2025-01-24 | |
| Study to Evaluate the Safety of ATR-04 ATR-04, Placebo - Epidermal Growth Factor, Papulopustular Rosacea | Phase 1 / Phase 2 | Withdrawn | Azitra Inc. | 2024-01-01 | 2025-10-03 | |
| PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea PF-07038124, Placebo Ointment - Seborrheic Dermatitis, Papulopustular Rosacea | Phase 2 | Terminated | Icahn School of Medicine at Mount Sinai | 32 | 2023-07-19 | 2026-08-14 |
| Study of TP-04 in Participants With Papulopustular Rosacea Lotilaner Gel, 2.0%, Vehicle control gel - Papulopustular Rosacea | Phase 2 | Completed | Tarsus Pharmaceuticals, Inc. | 37 | 2023-03-01 | 2023-11-24 |
| A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2) DFD-29, Doxycycline, Placebo - Papulopustular Rosacea | Phase 3 | Completed | Journey Medical Corporation | 330 | 2022-03-29 | 2024-12-03 |
| A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea. DFD-29, Doxycycline, Placebo - Papulopustular Rosacea | Phase 3 | Completed | Journey Medical Corporation | 323 | 2022-03-14 | 2024-12-03 |
| Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea Rifaximin, Placebo - Papulopustular Rosacea | Phase 2 | Completed | Alfasigma S.p.A. | 216 | 2021-10-05 | 2024-04-24 |
| A Safety and Efficacy Study to Evaluate Rosacea AIV001, Vehicle - Papulopustular Rosacea | Phase 1 / Phase 2 | Withdrawn | AiViva BioPharma, Inc. | 2021-07-01 | 2024-12-17 | |
| Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties Encapsulated Benzoyl Peroxide Cream - Papulopustular Rosacea | Phase 1 | Completed | Sol-Gel Technologies, Ltd. | 31 | 2020-06-10 | 2023-04-18 |
| Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea minocycline topical gel, topical gel vehicle - Papulopustular Rosacea | Phase 2 | Unknown | BioPharmX, Inc. | 207 | 2018-09-18 | 2019-07-10 |
| A Long-Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea S5G4T-1 - Papulopustular Rosacea | Phase 3 | Terminated | Sol-Gel Technologies, Ltd. | 547 | 2018-09-12 | 2021-12-15 |
| Safety and Efficacy of Rifaximin in Patients With Papulopustular Rosacea and Positive Lactulose Breath Test Rifaximin delayed release 400 mg tablet, Placebo - Papulopustular Rosacea | Phase 2 | Unknown | Alfasigma S.p.A. | 236 | 2018-06-22 | 2019-03-11 |
| A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea S5G4T-1, S5G4T-2 - Papulopustular Rosacea | Phase 3 | Completed | Sol-Gel Technologies, Ltd. | 372 | 2018-06-21 | 2021-12-15 |
| A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea S5G4T-1, S5G4T-2 - Papulopustular Rosacea | Phase 3 | Completed | Sol-Gel Technologies, Ltd. | 361 | 2018-06-18 | 2021-12-14 |
| Study to Evaluate the Safety and Efficacy of Topical Minocycline Gel in Patients With Papulopustular Rosacea 1% Topical Minocycline Gel, 3% Topical Minocycline Gel, Topical Vehicle Gel - Rosacea, Papulopustular Rosacea | Phase 2 | Completed | Hovione Scientia Limited | 270 | 2017-10-30 | 2019-11-08 |
| A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea FMX103 1.5% - Papulopustular Rosacea | Phase 3 | Completed | Vyne Therapeutics Inc. | 504 | 2017-09-05 | 2022-01-18 |
| Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea Secukinumab - Papulopustular Rosacea | Phase 1 / Phase 2 | Completed | Anne Chang | 24 | 2017-06-21 | 2020-02-05 |
| Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea FMX-103 1.5%, FMX-103 3%, Vehicle foam (0%) - Rosacea, Papulopustular Rosacea | Phase 2 | Completed | Vyne Therapeutics Inc. | 233 | 2015-09-01 | 2017-02-15 |
Showing 20 of 37. Sign in to see all of them.
Rosacea (37) · Dermatitis, Seborrheic (1) · Primary hyperoxaluria type 2 (1) · Skin Diseases (1) · Telangiectasis (1) · cyclopia sequence (1)
Skin and Connective Tissue Diseases (37) · Skin Diseases (36) · Cardiovascular Diseases (1) · Dermatitis (1) · Sebaceous Gland Diseases (1) · Skin Diseases, Eczematous (1) · Skin Diseases, Papulosquamous (1) · Vascular Diseases (1)
Doxycycline (4) · azelaic acid (4) · Gels (3) · Metronidazole (3) · Aminolevulinic Acid (1) · Clascoterone (1) · Cromolyn Sodium (1) · Ivermectin (1) · N-(1-(3,5-difluoro-4-methanesulfonylaminophenyl)ethyl)-3-(2-propyl-6-trifluoromethylpyridine-3-yl)acrylamide (1) · Omiganan (1) · Rifaximin (1) · Saline Solution (1) · Sodium Chloride (1) · Tablets (1) · apremilast (1)
LEO Pharma (6) · Sol-Gel Technologies, Ltd. (4) · Galderma R&D (3) · Alfasigma S.p.A. (2) · Icahn School of Medicine at Mount Sinai (2) · Journey Medical Corporation (2) · Maruho Co., Ltd. (2) · Vyne Therapeutics Inc. (2) · AiViva BioPharma, Inc. (1) · Amorepacific Corporation (1) · Anne Chang (1) · Azitra Inc. (1) · BioPharmX, Inc. (1) · Cutera Inc. (1) · George Washington University (1)
United States (30) · Germany (5) · Canada (3) · Bulgaria (2) · South Korea (2) · China (1) · Czechia (1) · France (1) · Hungary (1) · Italy (1) · Poland (1) · Romania (1) · Russia (1) · Singapore (1) · Spain (1)
Srinivas R Sidgiddi, M.D. (2) · Alison Ehrlich, MD, MHS (1) · AnnaMarie Daniels (1) · Anne Chang, MD (1) · Benjamin Ungar (1) · Benjamin Ungar, MD (1) · BeomJoon Kim, Professor (1) · Jared Jagdeo, MD MS (1) · Jose Trevejo, MD, PhD (1) · Julian Mackay-Wiggan, MD, MS (1) · Kamaria Nelson, MD (1) · Michael Graeber, M.D. (1) · Mitchell Goldman, MD (1) · Stephen Ronan, MD (1)
PMID 37636253, PMID 40042869, PMID 20645521, PMID 26244354, PMID 29396702, PMID 37636251, PMID 39148964
2017 (1), 2025 (1)